India, July 20 -- Japan-based Takeda Biopharmaceuticals on Monday announced that India's drug regulator has granted market authorisation to its anti-dengue vaccine QDENGA, making it the first dengue vaccine approved for use in the country.

"The Drugs Controller General of India (DCGI) has granted market authorisation (CT-20, New Drugs and Clinical Trials (NDCT) Rules, 2019) for QDENGA, Takeda's dengue vaccine for the prevention of dengue disease in individuals aged 4-60," Takeda Biopharmaceuticals India said in a statement.

QDENGA is the first dengue vaccine approved in India and can be administered to individuals irrespective of previous dengue exposure, without requiring pre-vaccination testing, the company said.

Dengue continues to ...